S&P 500   4,076.26 (-0.09%)
DOW   34,388.24 (-0.58%)
QQQ   293.60 (+0.08%)
AAPL   148.37 (+0.23%)
MSFT   254.79 (-0.14%)
META   120.11 (+1.70%)
GOOGL   101.18 (+0.19%)
AMZN   95.54 (-1.04%)
TSLA   194.88 (+0.09%)
NVDA   171.42 (+1.29%)
NIO   12.14 (-5.01%)
BABA   86.12 (-1.64%)
AMD   77.10 (-0.68%)
T   19.14 (-0.73%)
MU   55.22 (-4.22%)
CGC   3.81 (+5.25%)
F   14.06 (+1.15%)
GE   85.46 (-0.59%)
DIS   98.09 (+0.22%)
AMC   8.89 (+22.96%)
PYPL   78.56 (+0.19%)
PFE   50.85 (+1.44%)
NFLX   317.78 (+4.01%)
S&P 500   4,076.26 (-0.09%)
DOW   34,388.24 (-0.58%)
QQQ   293.60 (+0.08%)
AAPL   148.37 (+0.23%)
MSFT   254.79 (-0.14%)
META   120.11 (+1.70%)
GOOGL   101.18 (+0.19%)
AMZN   95.54 (-1.04%)
TSLA   194.88 (+0.09%)
NVDA   171.42 (+1.29%)
NIO   12.14 (-5.01%)
BABA   86.12 (-1.64%)
AMD   77.10 (-0.68%)
T   19.14 (-0.73%)
MU   55.22 (-4.22%)
CGC   3.81 (+5.25%)
F   14.06 (+1.15%)
GE   85.46 (-0.59%)
DIS   98.09 (+0.22%)
AMC   8.89 (+22.96%)
PYPL   78.56 (+0.19%)
PFE   50.85 (+1.44%)
NFLX   317.78 (+4.01%)
S&P 500   4,076.26 (-0.09%)
DOW   34,388.24 (-0.58%)
QQQ   293.60 (+0.08%)
AAPL   148.37 (+0.23%)
MSFT   254.79 (-0.14%)
META   120.11 (+1.70%)
GOOGL   101.18 (+0.19%)
AMZN   95.54 (-1.04%)
TSLA   194.88 (+0.09%)
NVDA   171.42 (+1.29%)
NIO   12.14 (-5.01%)
BABA   86.12 (-1.64%)
AMD   77.10 (-0.68%)
T   19.14 (-0.73%)
MU   55.22 (-4.22%)
CGC   3.81 (+5.25%)
F   14.06 (+1.15%)
GE   85.46 (-0.59%)
DIS   98.09 (+0.22%)
AMC   8.89 (+22.96%)
PYPL   78.56 (+0.19%)
PFE   50.85 (+1.44%)
NFLX   317.78 (+4.01%)
S&P 500   4,076.26 (-0.09%)
DOW   34,388.24 (-0.58%)
QQQ   293.60 (+0.08%)
AAPL   148.37 (+0.23%)
MSFT   254.79 (-0.14%)
META   120.11 (+1.70%)
GOOGL   101.18 (+0.19%)
AMZN   95.54 (-1.04%)
TSLA   194.88 (+0.09%)
NVDA   171.42 (+1.29%)
NIO   12.14 (-5.01%)
BABA   86.12 (-1.64%)
AMD   77.10 (-0.68%)
T   19.14 (-0.73%)
MU   55.22 (-4.22%)
CGC   3.81 (+5.25%)
F   14.06 (+1.15%)
GE   85.46 (-0.59%)
DIS   98.09 (+0.22%)
AMC   8.89 (+22.96%)
PYPL   78.56 (+0.19%)
PFE   50.85 (+1.44%)
NFLX   317.78 (+4.01%)
NASDAQ:CRBP

Corbus Pharmaceuticals - CRBP Stock Forecast, Price & News

$0.15
-0.04 (-21.85%)
(As of 12/1/2022 02:12 PM ET)
Add
Compare
Today's Range
$0.14
$0.17
50-Day Range
$0.11
$0.19
52-Week Range
$0.10
$0.90
Volume
389,385 shs
Average Volume
1.95 million shs
Market Capitalization
$19.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Corbus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
3.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.65
Upright™ Environmental Score
News Sentiment
0.93mentions of Corbus Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.25) to ($0.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

787th out of 1,047 stocks

Pharmaceutical Preparations Industry

385th out of 512 stocks

CRBP stock logo

About Corbus Pharmaceuticals (NASDAQ:CRBP) Stock

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRBP Stock News Headlines

Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Corbus Pharmaceuticals: Q4 Earnings Insights
See More Headlines
Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRBP Company Calendar

Last Earnings
11/12/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/14/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRBP
Employees
41
Year Founded
N/A

Profitability

Net Income
$-45,640,000.00
Pretax Margin
-36,209.27%

Debt

Sales & Book Value

Annual Sales
$880,000.00
Book Value
$0.33 per share

Miscellaneous

Free Float
115,008,000
Market Cap
$19.04 million
Optionable
Optionable
Beta
1.82

Key Executives

  • Dr. Yuval Cohen Ph.D. (Age 47)
    CEO & Director
    Comp: $846.92k
  • Mr. Sean F. Moran CPA (Age 64)
    M.B.A., CPA, MBA, Chief Financial Officer
    Comp: $542k
  • Mr. Craig Stuart Millian M.B.A. (Age 53)
    Chief Operating Officer
    Comp: $542k
  • Dr. Rachael Brake Ph.D. (Age 50)
    Chief Scientific Officer
  • Ted Jenkins
    Sr. Director of Investor Relations & Corp. Communications
  • Ms. Lindsey Smith
    Head of Corp. Communications & Patient Advocacy
  • Ms. Christina Bertsch
    Head of HR
  • Scott Constantine
    Sr. Director & Head of Clinical Operations













CRBP Stock - Frequently Asked Questions

How have CRBP shares performed in 2022?

Corbus Pharmaceuticals' stock was trading at $0.6157 at the beginning of 2022. Since then, CRBP shares have decreased by 74.5% and is now trading at $0.1571.
View the best growth stocks for 2022 here
.

When is Corbus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our CRBP earnings forecast
.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) released its quarterly earnings results on Friday, November, 12th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.10. The biopharmaceutical company earned $0.10 million during the quarter, compared to analysts' expectations of $0.81 million.

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include ETF Managers Group LLC (3.76%), Vanguard Group Inc. (3.23%), Pinnacle Associates Ltd. (0.66%), Renaissance Technologies LLC (0.63%), ExodusPoint Capital Management LP (0.29%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Barbara White, Craig Stuart Millian, Robert Paul Discordia, Sean F Moran and Yuval Cohen.
View institutional ownership trends
.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $0.16.

How much money does Corbus Pharmaceuticals make?

Corbus Pharmaceuticals (NASDAQ:CRBP) has a market capitalization of $19.68 million and generates $880,000.00 in revenue each year. The biopharmaceutical company earns $-45,640,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The official website for the company is www.corbuspharma.com. The biopharmaceutical company can be reached via phone at (617) 963-0100, via email at ir@corbuspharma.com, or via fax at 617-663-6085.

This page (NASDAQ:CRBP) was last updated on 12/1/2022 by MarketBeat.com Staff